NasdaqGM:RYTMBiotechs
Rhythm Pharmaceuticals (RYTM) Revenue Ramp With US$201.9m TTM Loss Tests Bullish Narratives
Rhythm Pharmaceuticals (RYTM) has just reported Q1 2026 results, with trailing twelve month revenue of about US$189.8 million and a net loss of roughly US$201.9 million, which translates into basic EPS of US$3.11 in losses. Over recent quarters, revenue has moved from US$41.8 million in Q4 2024 to US$57.3 million in Q4 2025, while quarterly basic EPS losses have ranged between about US$0.73 and US$0.82 per share. For investors, the focus is now on whether that expanding top line can...